$0.0010
+0 (+0%)
At Close: Jun 03, 2026
FY2021 EPS Estimates for Trevena, Inc. (NASDAQ:TRVN) Boosted by Oppenheimer
06:44am, Saturday, 20'th Nov 2021 Dakota Financial News
Trevena, Inc. (NASDAQ:TRVN) Stock analysts at Oppenheimer increased their FY2021 earnings per share estimates for shares of Trevena in a research report issued to clients and investors on Monday, November 15th. Oppenheimer analyst J. Jones now forecasts that the biopharmaceutical company will post earnings of ($0.31) per share for the year, up from their []
Analysts Predicting A Spike In Trevena Inc. (NASDAQ: TRVN)?
02:30pm, Friday, 19'th Nov 2021 Stocks Register
Trevena Inc. (NASDAQ:TRVN) price on Thursday, November 18, fall -7.11% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.74. A look at the stocks price movement, the close in the last trading session was $0.79, moving within a range at $0.73 and $0.7979. The beta value (5-Year Analysts Predicting A Spike In Trevena Inc. (NASDAQ: TRVN)? Read More »
Flaming Stock: Trevena, Inc. (NASDAQ:TRVN), United Microelectronics Corporation (NYSE:UMC)
11:58am, Wednesday, 17'th Nov 2021 Stock Equity
Trevena, Inc. (TRVN) with the stream of -3.78% also noticed, India United Microelectronics Corporation (UMC) encountered a rapid change of -0.62% in the last hour of Tuesdays trading session. Trevena, The post Flaming Stock: Trevena, Inc. (NASDAQ:TRVN), United Microelectronics Corporation (NYSE:UMC) appeared first on Stocks Equity .
Trevena (NASDAQ:TRVN) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
01:02pm, Tuesday, 16'th Nov 2021 Dakota Financial News
Trevena (NASDAQ:TRVN) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01, MarketWatch Earnings reports. Trevena had a negative net margin of 1,194.62% and a negative return on equity of 40.89%. During the same period last year, the company []
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript
05:33pm, Monday, 15'th Nov 2021 Seeking AlphaTrevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
05:25pm, Monday, 15'th Nov 2021 Zacks Investment Research
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
01:55pm, Monday, 15'th Nov 2021
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript
12:33pm, Monday, 15'th Nov 2021
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript
Trevena EPS beats by $0.01, misses on revenue
12:02pm, Monday, 15'th Nov 2021 Seeking AlphaThe Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
07:00am, Monday, 08'th Nov 2021
Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
10:45am, Sunday, 03'rd Oct 2021
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informat
Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients
09:13am, Thursday, 30'th Sep 2021
Trevena Inc (NASDAQ: TRVN) has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The results showed that TRV027 was well-tolerate
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
07:00am, Thursday, 30'th Sep 2021
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
07:00am, Friday, 17'th Sep 2021
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ce
Sign In
Buy TRVN